November 29, 2016 - By Darrin Black
Thomas Craig is the director of Idexx Laboratories Inc De. He recently unloaded 8,500 shares in the company with the trade value amounting to around $1,020,519 U.S. Dollars. This is according to the documented price of $120.1 for every share. Mr. Thomas currently holds 24,283 shares, accounting for 0.03% of Idexx Laboratories Inc De’s total market capitalization. The date was 28-11-2016 when Thomas made the sale, and it was revealed in a report with the SEC, accessible for free on this website.
Out of 7 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. $98 is the highest target while $69.50 is the lowest. The $82.90 average target is -30.69% below today’s ($119.6) stock price. IDEXX Laboratories has been the topic of 13 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Market Perform” rating given on Friday, August 28 by Raymond James. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, July 20. Stifel Nicolaus maintained it with “Buy” rating and $85 target price in Monday, March 21 report. The rating was maintained by Stifel Nicolaus on Thursday, October 29 with “Buy”. Credit Suisse maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Wednesday, April 13 with “Outperform” rating. The firm has “Outperform” rating by Credit Suisse given on Thursday, February 4. The rating was initiated by CL King with “Neutral” on Friday, April 1. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 13 report. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, July 23 report. Bank of America reinitiated IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Thursday, September 29 with “Neutral” rating.
Insitutional Activity: The institutional sentiment decreased to 1.14 in 2016 Q2. Its down 0.20, from 1.34 in 2016Q1. The ratio dropped, as 27 funds sold all IDEXX Laboratories, Inc. shares owned while 123 reduced positions. 79 funds bought stakes while 122 increased positions. They now own 77.90 million shares or 5.94% less from 82.81 million shares in 2016Q1.
North Amer Mngmt Corporation last reported 0.15% of its portfolio in the stock. Lafleur Godfrey Ltd Limited Liability Company last reported 10,025 shares in the company. Nomura Asset Limited last reported 9,450 shares in the company. Axa accumulated 0.02% or 42,400 shares. Credit Suisse Ag last reported 576,467 shares in the company. Fuller And Thaler Asset Mgmt has 0% invested in the company for 1,300 shares. Proshare Ltd holds 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 10,379 shares. Mairs & holds 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 3,998 shares. Teachers Retirement Sys Of The State Of Kentucky has 0.03% invested in the company for 22,800 shares. Moreover, Chilton Ltd Liability Corp has 3.29% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 998,851 shares. The New York-based Cipher Ltd Partnership has invested 0.05% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Biondo Inv Limited Liability, a Pennsylvania-based fund reported 82,691 shares. First Personal Fincl Svcs has invested 0.02% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Kanaly has 0% invested in the company for 133 shares. Regions Fincl holds 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 5,681 shares.
Insider Transactions: Since August 4, 2016, the stock had 0 insider buys, and 7 selling transactions for $19.47 million net activity. Another trade for 9,924 shares valued at $1.10M was sold by HENDERSON REBECCA M. The insider JOHNSON BARRY C sold $1.11 million. END WILLIAM T sold $549,359 worth of stock or 5,000 shares. 49,560 shares were sold by Williams Michael J PhD, worth $5.40 million on Monday, August 8. On Thursday, August 4 AYERS JONATHAN W sold $6.46 million worth of the stock or 60,000 shares.
About 450,119 shares traded hands. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 48.08% since April 25, 2016 and is uptrending. It has outperformed by 42.07% the S&P500.
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The company has a market cap of $10.72 billion.
According to Zacks Investment Research, “IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection, and information products to the animal health industry as well as quality assurance products and services to the food and water industries.”
Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on February, 3. They expect $0.51 earnings per share, up 6.25% or $0.03 from last year’s $0.48 per share. IDXX’s profit will be $45.71M for 58.63 P/E if the $0.51 EPS becomes a reality. After $0.62 actual earnings per share reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts -17.74% negative EPS growth.
More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Prnewswire.com which released: “IDEXX Laboratories Announces Departure of Executive Vice President Michael ..” on November 15, 2016, also Fool.com with their article: “IDEXX Laboratories, Inc. Sees More Growth Ahead” published on May 02, 2016, Fool.com published: “Why IDEXX Laboratories, Inc. Reported Higher Today” on August 02, 2016. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: Streetinsider.com and their article: “Form 4 IDEXX LABORATORIES INC For: Nov 23 Filed by: CRAIG THOMAS” published on November 29, 2016 as well as Prnewswire.com‘s news article titled: “IDEXX Laboratories to Host 2016 Investor Day” with publication date: August 08, 2016.
IDEXX Laboratories, Inc., incorporated in 1983, develops, makes and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Firm operates through three divisions: diagnostic and information technology services and products for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller divisions that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black